In people with Parkinson's disease, neuropsychiatric signs and symptoms are common
throughout the disease course. These symptoms can be disabling and as clinically relevant …

Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

Affective disorders, cognitive decline, and psychosis have long been recognized as common
in Parkinson disease (PD), and other psychiatric disorders include impulse control …

The central cholinergic system includes the basal forebrain nuclei, mainly projecting to the
cortex, the mesopontine tegmental nuclei, mainly projecting to the thalamus and subcortical …

Background and purpose Well‐structured hallucinations in Parkinson's disease (PD) are
associated with poor prognosis and dementia. However, the predictive value of minor …

Abstract Background Dementia with Lewy bodies (DLB) is the second most common form of
dementia. Current symptomatic treatment with medications remains inadequate. Deep brain …

Highlights•The cholinergic system degenerates in many neuropsychiatric
disorders.•Cholinergic drugs typically increase all cholinergic activity.•Targeting M1 and M4 …

Parkinson disease (PD) psychosis (PDP) is a spectrum of illusions, hallucinations and
delusions that are associated with PD throughout its disease course. Psychotic phenomena …

One of the first identified neurotransmitters in the brain, acetylcholine, is an important
modulator that drives changes in neuronal and glial activity. For more than two decades, the …

Background Neuroanatomical alterations underlying psychosis in Parkinson's Disease
(PDP) remain unclear. We carried out a meta-analysis of MRI studies investigating the …